Exploring the clinical outcomes and safety profile of inetetamab treatment in metastatic breast cancer patients: A multicenter assessment of a Chinese-origin recombinant Anti-HER2 monoclonal antibody

Exploring the clinical outcomes and safety profile of inetetamab treatment in metastatic breast cancer patients: A multicenter assessment of a Chinese-origin recombinant Anti-HER2 monoclonal antibody

Background: Inetetamab is a novel recombinant humanized anti-HER2 monoclonal antibody. This study aimed to evaluate the efficacy and safety of inetetamab and predictive factors for response in HER2-positive metastatic breast cancer (MBC) patients. Methods: A cohort of HER2-positive MBC patients who...

Full description

Bibliographic Details
Main Authors: Binliang Liu, Ning Xie, Can Tian, Ronghua Feng, Zhe-Yu Hu, Jing Li, Liping Liu, Huawu Xiao, Xiaohong Yang, Mengsi Zeng, Hui Wu, Jun Lu, Jianxiang Gao, Xuming Hu, Min Cao, Zhengrong Shui, Yu Tang, Tao Wu, Quchang Ouyang
Format: Article
Language:English
Published: Elsevier 2023-12-01
Series:Breast
Subjects:
Adverse events
Breast cancer
Effectiveness
HER2-Positive
Inetetamab
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977623005738

Internet

http://www.sciencedirect.com/science/article/pii/S0960977623005738

Similar Items